New combo attack on sarcoma aims to delay return of cancer
NCT ID NCT07049848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adults with high-risk soft tissue sarcoma that can be removed by surgery. It tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy, radiation, and surgery can delay the cancer from coming back. About 50 participants will receive the combination and be monitored for side effects and relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells